Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

The Retina World Congress showcases global innovations in surgical and medical retina, highlighting emerging treatments and ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg ...

Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration (AMD ...

This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...